See what sets
3M^™ V.A.C.®
Therapy apart

Since its introduction in 1995, V.A.C.^® Therapy has been selected to treat more than 10 million wounds worldwide. More than 75% of published Negative Pressure Wound Therapy (NPWT) clinical evidence is based on V.A.C.^® Therapy.

Wound healing progression involves removal of barriers to wound healing (such as exudate), adequate perfusion to the wound bed and production of granulation tissue. Successful healing involves addressing wounds that may be stalled in the inflammatory and proliferative phases of wound healing. Many passive and active therapies have been developed to address those barriers of wound healing, including NPWT. NPWT is utilized across the continuum of care and has substantial amounts of clinical outcomes data demonstrating efficacy in creating an environment that promotes healing in a wide variety of wounds.

The 3M^™ V.A.C.^® Therapy System was introduced in 1995 as the first commercial NPWT system. 3M^™ has continued to lead the way in the development of new technologies and therapies designed to make wound healing manageable for caregivers and more comfortable for patients around the world. The V.A.C.^® Therapy System (3M^™ V.A.C.^® Therapy) is indicated for patients with chronic, acute, traumatic, sub-acute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure or venous insufficiency), flaps and grafts.

Acute Care Setting

To learn more about V.A.C.^® Therapy in the acute setting, view the brochure.

Post-Acute Care Setting

To learn more about V.A.C.^® Therapy in the post-acute setting, view the brochure.